anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The patient should be informed that carbidopa and levodopa tablets are an immediate-release formulation of carbidopa and levodopa that is designed to begin release of ingredients within 30 minutes. It is important that carbidopa and levodopa tablets be taken at regular intervals according to the schedule outlined by the physician. The patient should be cautioned not to change the prescribed dosage regimen and not to add any additional antiparkinson medications, including other carbidopa and levodopa preparations, without first consulting the physician.

Patients should be advised that sometimes a ‘wearing-off’ effect may occur at the end of the dosing interval. The physician should be notified if such response poses a problem to lifestyle.

Patients should be advised that occasionally, dark color (red, brown, or black) may appear in saliva, urine, or sweat after ingestion of carbidopa and levodopa. Although the color appears to be clinically insignificant, garments may become discolored.

The patient should be advised that a change in diet to foods that are high in protein may delay the absorption of levodopa and may reduce the amount taken up in the circulation. Excessive acidity also delays stomach emptying, thus delaying the absorption of levodopa. Iron salts (such as in multivitamin tablets) may also reduce the amount of levodopa available to the body. The above factors may reduce the clinical effectiveness of the levodopa or carbidopa and levodopa therapy.

Patients should be alerted to the possibility of sudden onset of sleep during daily activities, in some cases without awareness or warning signs, when they are taking dopaminergic agents, including levodopa. Patients should be advised to exercise caution while driving or operating machinery and that if they have experienced somnolence and/or sudden sleep onset, they must refrain from these activities (see WARNINGS: Falling Asleep During Activities of Daily Living and Somnolence).

There have been reports of patients experiencing intense urges to gamble, increased sexual urges, and other intense urges, and the inability to control these urges while taking one or more of the medications that increase central dopaminergic tone and that are generally used for the treatment of Parkinson’s disease, including carbidopa and levodopa. Although it is not proven that the medications caused these events, these urges were reported to have stopped in some cases when the dose was reduced or the medication was stopped. Prescribers should ask patients about the development of new or increased gambling urges, sexual urges or other urges while being treated with carbidopa and levodopa. Patients should inform their physician if they experience new or increased gambling urges, increased sexual urges, or other intense urges while taking carbidopa and levodopa. Physicians should consider dose reduction or stopping the medication if a patient develops such urges while taking carbidopa and levodopa (see PRECAUTIONS: Impulse Control/Compulsive Behaviors).
During treatment period 3, subjects will receive 5-HTP 100 mg (5-HTP, Basic Vitamins) and matching placebo for EM 1 mg (ascorbic acid powder). One of each capsule (both size 00) will be taken three times per day for four weeks.
Creatinine and Blood Urea Nitrogen: Of hypertensive patients with no apparent preexisting renal disease, about 2% have sustained increases in serum creatinine to at least 150% of their baseline values while receiving Lotensin, but most of these increases have disappeared despite continuing treatment. A much smaller fraction of these patients (less than 0.1%) developed simultaneous (usually transient) increases in blood urea nitrogen and serum creatinine. None of these increases required discontinuation of treatment. Increases in these laboratory values are more likely to occur in patients with renal insufficiency or those pretreated with a diuretic and, based on experience with other ACE inhibitors, would be expected to be especially likely in patients with renal artery stenosis (see PRECAUTIONS, General).

Potassium: Since benazepril decreases aldosterone secretion, elevation of serum potassium can occur. Potassium supplements and potassium-sparing diuretics should be given with caution, and the patient’s serum potassium should be monitored frequently (see PRECAUTIONS).

Hemoglobin: Decreases in hemoglobin (a low value and a decrease of 5 g/dL) were rare, occurring in only 1 of 2,014 patients receiving Lotensin alone and in 1 of 1,357 patients receiving Lotensin plus a diuretic. No U.S. patients discontinued treatment because of decreases in hemoglobin.

Other (causal relationships unknown): Clinically important changes in standard laboratory tests were rarely associated with Lotensin administration. Elevations of uric acid, blood glucose, serum bilirubin, and liver enzymes (see WARNINGS) have been reported, as have scattered incidents of hyponatremia, electrocardiographic changes, leukopenia, eosinophilia, and proteinuria. In U.S. trials, less than 0.5% of patients discontinued treatment because of laboratory abnormalities.
The invention relates to the technical field of healthcare products, especially to a foot massage care powder and a preparation method thereof. The foot massage care powder is prepared by the following raw materials by weight percent: 35-50 % of yew leaves and/or yew twigs skin, 8-13 % of Ovate Catalpa, 35-40 % of water caltrop stems and/or pedicles and 7-12 % of Sophora flavescens. The preparation method comprises respectively collecting the yew leaves, the yew twigs skin, the Ovate Catalpa, the water caltrop stems and pedicles and the Sophora flavescens, drying in the sun for later use, selecting the above raw materials, weighing according to weight percentage, preparing into powder, mixing, and packaging into bags. According to the invention, components of the foot massage care powder are effectively and reasonably matched, and thus the foot massage care powder plays a good role in the prevention and treatment for skin diseases and body care. By using in a way of powder, surface areas of traditional Chinese medicine is increased, dissolution rate of active components of the powder is greatly increased, thereby not only strengthening the efficacy but also saving herbs, and reaching a double benefit. According to the invention, the preparation technology is simple, the preparation is easy, the investment cost is low, and the powder is prepared into bags to greatly facilitate the foot massage care.
Described herein are therapeutics that can modulate (e.g. increase) T-reg cell proliferation, survival, activation and/or function. In some embodiments, the modulation is selective or specific for the T-reg cells. The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same. In another aspect, the present embodiments provide compositions, e.g., pharmaceutically acceptable compositions, which include a therapeutic compound (IL-2 mutein) described herein, formulated together with a pharmaceutically acceptable carrier. Also within the scope of the invention is a kit comprising a therapeutic compound described herein.
A novel system and methodology for dietary and medical treatment planning wherein meals and treatment plans are specifically individualized for a user according to a number of unique characteristics associated with that user. These characteristics are provided to the system of the present invention and one or more resulting meal plans and/or therapies are generated. According to the present invention, particular dieter specific characteristics that may be considered in developing the meal plan include daily caloric limitations and or recommendations, daily nutritional requirements including minimum and maximum vitamin, mineral, water, and electrolyte intake as well as specific genetic characteristics concerning the individual. Dieter food preferences and other factors may also be considered. The system of the present invention uses this dieter specific information to generate one or more meal plans for that dieter in connection with an ingredient, food, supplement, drug and recipe database containing a universe of foods, supplements, and drugs available for generating meals and treatment plans in accordance with the diet. The system of the present invention may function as a standalone application or it may be web-based wherein users may access the application on a server accessible through the internet or some other public or private network.
The co-occurrence and familial clustering of neurodevelopmental disorders and immune disorders suggest shared genetic risk factors. Based on genome-wide association summary statistics from five neurodevelopmental disorders and four immune disorders, we conducted genome-wide, local genetic correlation and polygenic overlap analysis. We further performed a cross-trait GWAS meta-analysis. Pleotropic loci shared between the two categories of diseases were mapped to candidate genes using multiple algorithms and approaches. Significant genetic correlations were observed between neurodevelopmental disorders and immune disorders, including both positive and negative correlations. Neurodevelopmental disorders exhibited higher polygenicity compared to immune disorders. Around 50%-90% of genetic variants of the immune disorders were shared with neurodevelopmental disorders. The cross-trait meta-analysis revealed 154 genome-wide significant loci, including 8 novel pleiotropic loci. Significant associations were observed for 30 loci with both types of diseases. Pathway analysis on the candidate genes at these loci revealed common pathways shared by the two types of diseases, including neural signaling, inflammatory response, and PI3K-Akt signaling pathway. In addition, 26 of the 30 lead SNPs were associated with blood cell traits. Neurodevelopmental disorders exhibit complex polygenic architecture, with a subset of individuals being at a heightened genetic risk for both neurodevelopmental and immune disorders. The identification of pleiotropic loci has important implications for exploring opportunities for drug repurposing, enabling more accurate patient stratification, and advancing genomics-informed precision in the medical field of neurodevelopmental disorders.
The invention discloses a biomarker of mental disorder and application thereof. And (3) carrying out microbial gene chip hybridization research on intestinal flora microbial genomes in the fecal samples of the mental disorder group and the healthy control group to describe fecal microbial communities and functional gene characteristics. Through difference detection, discriminant analysis and machine learning, 15 functional genes are finally identified, and the functional genes can be used as biomarkers to distinguish mental disorder groups with high accuracy. The biomarkers are selected from at least 10 of the following group of 15 genes. The 15 genes are significantly different in intestinal flora in psychotic and healthy people. The invention also discloses a medicament for treating mental disorder, a method for producing or screening the medicament for treating mental disorder and a kit for detecting mental disorder, wherein the medicament can change the quantity or expression of the genes.
The Light-Heart study is randomized, double-blind, controlled trial of 8 weeks of morning BWL therapy, compared with DRL in older, Stage B HF patients with clinically significant levels of depressive symptoms. The primary hypothesis of the proposed study is that compared to DRL, BWL therapy will be associated with a significantly greater reduction in depressive symptoms. Important information about compliance and tolerability associated with the BWL intervention in Stage B HF patients will also be gathered. The investigators will examine whether BWL therapy is associated with greater improvements in quality of life and subjective functioning compared to DRL. Finally, the researchers will investigate whether BWL is associated with a sustained improvement in depressive symptoms 2 and 4 weeks following the end of the intervention compared to DRL.

One hundred twenty-two older adults (≥60 years) with Stage B HF and depressive symptoms (Beck Depression Inventory/BDI score ≥10) will be recruited from several University of California, San Diego (UCSD) and Veteran's Affairs (VA) cardiology clinics. The baseline assessment will include evaluation of depressive symptoms (BDI), quality of life (Quality of Life Enjoyment and Satisfaction questionnaire), subjective functioning (Short Form-36), and an assessment of patient expectations regarding the study intervention (single question, 5 point scale). These measures will be assessed again after 4 and 8 weeks of treatment and at 2 and 4 weeks following the end of the BWL therapy intervention along with side effects (Frequency, Intensity, and Burden of Side Effects Rating).

Participants will be randomized to receive BWL (n=61) or DRL (n=61) light therapy boxes (Litebook® Elite; Litebook® Inc., Medicine Hat, CA) to use at home for 60 minutes each morning for 8 weeks. If participants are currently receiving treatment (e.g. antidepressant therapy), participants will continue their usual treatment while in the study. Participants will be told that the effects of a particular light therapy protocol on mood and functioning is being investigated. Participants will be made aware that there is a treatment condition of interest and a comparison condition and that participants will be randomly assigned to one or the other group. Participants will not be told that different colors of light are being used or that BWL is the treatment of interest. The Litebooks® will look identical except for the color of the light. Weekly telephone calls will encourage compliance, and compliance meters will record when the Litebooks® are turned on or off. A blood sample will also be collected from each patient to assess for biomarkers.
Pain is a common co-morbidity for HIV-positive patients.Prevalence studies suggest that, on average, half of all HIV-positive persons suffer pain. Chronic pain can lead to heavy alcohol use among HIV-positive persons, which may in turn be a barrier to treatment/control of HIV and contribute to spread of HIV. Thus there is an urgent need to address pain among persons with HIV. It is timely and relevant to conduct research on gabapentin, as it has emerged as one of the most commonly prescribed non-opioid medications for pain despite the fact that gabapentin is only FDA approved for "post-herpetic neuralgia" and the literature to support its use for generalized chronic pain is limited. And yet, gabapentin has demonstrated benefits for treatment of alcohol use disorder, and therefore, like naltrexone, it could have a specific role for treating patients with chronic pain and unhealthy alcohol use. This study is a 3-arm pilot, randomized, double-blinded, placebo-controlled study of low-dose naltrexone and gabapentin vs. placebo among HIV-positive persons with heavy alcohol use and chronic pain to provide estimates of their effects on 1) pain (both self-reported and experimental/cold pressor test; 2) inflammation (i.e., levels of inflammatory cytokines IL-6, IL-1β, IL-10, and TNF-α); and 3) measures of HIV control (CD4 count and viral load).
BACKGROUND: Integrating spiritual aspects into treatment plans can release essential resources for coping with chronic pain. However, some spiritual aspects may also induce distress and hinder the coping process. There is a lack of evidence regarding how to perform the clinical tasks of exploring spiritual aspects and of instruments assessing related competencies. Therefore, we developed a web-based learning module to provide education on the subject alongside corresponding assessment instruments. The module presents the InSpiRe (Integration of Spirituality and/or Religion in patient encounters) protocol. The instruments encompass cognitive, affective, and behavioral dimensions.
METHODS: This paper aims to determine (i) the learning effects associated with completing the web-based spiritual-care learning module and (ii) the reliability and validity of the instruments employed. To address these aims, we conducted a pre-test/post-test trial with N = 32 randomly selected fourth-year medical students. During the pre-test, we assessed the students' knowledge, attitudes, and self-efficacy regarding exploring spiritual aspects. For this purpose, we developed a short-answer knowledge test, an attitude questionnaire, and a self-efficacy scale. Additionally, the students explored spiritual aspects with a simulated patient portraying a person with chronic pain. Three trained raters evaluated the students' performances using a self-developed scale. In the intervention phase, the students completed the 45-minute learning module on a personal computer. The module presented InSpiRe-related content as text and step-by-step video demonstrations, including hints that denote critical actions. The subsequent post-test was identical to the pre-test.
RESULTS: The internal consistency was suitable for all respective instruments, and there was an indication of solid validity of the performance test. After completing the spiritual care learning module, the students showed statistically significant increases in knowledge scores and significant positive shifts in their attitudes and levels of self-efficacy regarding exploring spiritual aspects. They also attained significantly higher performance scores in the same regard.
CONCLUSIONS: Completing the spiritual-care module is associated with meaningful learning effects on cognitive, affective, and behavioral dimensions related to exploring spiritual aspects, as demonstrated in the post-test conducted shortly after the intervention. Due to good reliability and validity scores, the self-developed instruments can be applied appropriately.
A method for automatically and iteratively updating patient encounter reports based on recognized patterns of occurrences. A patient's information is obtained prior to a visit to a healthcare facility. This information is compared to a set of guidelines. The result is a preliminary patient encounter report that may be presented to a physician as well as act as a preset trigger to generate financial transactions. The physician can edit the report due to his own preferences and the updated report automatically sent to a rules engine that examines the edits, on a physician, healthcare facility, and patient level and determines if changes to the existing guidelines need to be made. The new guidelines are sent to a predictor module so that upon subsequent visits by patients, new guidelines will appear on the preliminary patient encounter summary report along with other learned administrative and financial transactions within the system.
An improved formula of yerba mate health drink is disclosed, which includes dried tangerine peels, licorice roots, mints, Goji berries, dried yerba mate leaves and twigs (yerba mate tea), wherein the proportion of dried tangerine peels, licorice roots, mints, Goji berries, dried yerba mate leaves and twigs (yerba mate tea) is 1:1:1:2:4. Yerba mate is a species of the Ilex family, with the botanical name Ilex paraguariensis. Yerba mate is well known as the source of the beverage called mate, and is traditionally consumed in the subtropical zone of South America, including Northern Argentina, Paraguay, Uruguay, Southern Brazil, and Bolivia. When the dried yerba mate leaves and twigs are soaked in hot water to make tea, the tea is known as yerba mate tea, Paraguay tea or Brazilian tea. Mate tea consists of eleven kinds of polyphenols capable of eliminating free radicals, boosting immune system, improving internal body conditions, and reducing blood lipid with a better blood circulation resulting from its abundant unsaturated fatty acids. The present invention extracts the original juice of dried yerba mate leaves and twigs (yerba mate tea), so as to produce a convenient, high-quality and thirst-quenching drink capable of facilitating metabolism and maintaining the normal operation of cardiovascular system. The drink is rich in minerals including vitamins, iron, calcium, fibers, etc. for supplementing nutrition to human body and assisting in stool. Alternatively, the extracted original juice may be added with other functional materials, such as Chinese medicinal herbs including dried tangerine peels, licorice roots, mints, Goui berries, scented tea, green tea, various vitamin powders, edible calcium carbonate, and natural fruit sugar sparkling water, for being homogenized as a second-time extract to be bottled, canned, powdered, or compressed as tablets with various shapes including heart shape, shell shape, star shape, cube, etc., thereby forming a series of drinking products that can be ready for use or conveniently carried and brewed.
Approximately 15-50% of patients with Crohn's disease (CD) will require surgery within ten years following the diagnosis. The management of modifiable risk factors before surgery is essential to reduce postoperative complications and to promote a better postoperative recovery. Preoperative malnutrition reduced functional capacity, sarcopenia, immunosuppressive medications, anemia, and psychological distress are frequently present in CD patients. Multimodal prehabilitation consists of nutritional, functional, medical, and psychological interventions implemented before surgery, aiming at optimizing preoperative status and improve postoperative recovery. Currently, studies evaluating the effect of multimodal prehabilitation on postoperative outcomes specifically in CD are lacking. Some studies have investigated the effect of a single prehabilitation intervention, of which nutritional optimization is the most investigated. The aim of this narrative review is to present the physiologic rationale supporting multimodal surgical prehabilitation in CD patients waiting for surgery, and to describe its main components to facilitate their adoption in the preoperative standard of care.
PURPOSE: To obtain a medicine having obvious lipolytic action in adipose tissue and excellent effect of suppressing, inhibiting and improving of obesity by using a plant of family Citrus as an active component. CONSTITUTION: This lipolytic medicine contains a raw material, a squeezed solution, dried powder or a solvent-extracted material, etc., of a plant of family Citrus, preferably Citrus tangerina Tanaka or Citrus erythrosa Tanaka of genus Citrus as an active component. Said accelerating medicine is blended with a xanthine derivative (preferably aminophylline or theophylline, etc.), a β- adrenergic stimulant (preferably isoproterenol or dobutamine, etc.), an α2 - adrenergic depressant (preferably yohimbine or phentolamine, etc.) or a bipyridine derivative (preferably amrinone or milrinone, etc.) of preferably 0.01-20% to enhance the effect.
A medical device ( e.g. , an analyte sensor) that may be implanted within a living animal ( e.g. , a human) and may be used to measure an analyte ( e.g. , glucose or oxygen) in a medium ( e.g. , interstitial fluid, blood, or intraperitoneal fluid) within the animal. The medical device may include a polymer covering at least a portion of a surface of the medical device and a plurality of reactive oxygen species (ROS) scavenger molecules covalently linked to the polymer (e.g., to reduce degradation of an analyte indicator including the polymer).